Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Deep vein thrombosis (DVT) is a condition in which a clot forms in the deep veins, most commonly of the leg. It occurs in approximately 1 in 1,000 people. If left untreated, the clot can travel up to the lungs and cause a potentially life-threatening pulmonary embolism (PE). Previously, a DVT was treated with the anticoagulants heparin and vitamin K antagonists. However, two forms of novel oral anticoagulants (NOACs) have been developed: oral direct thrombin inhibitors (DTI) and oral factor Xa inhibitors. The new drugs have characteristics that may be favourable over conventional treatment, including oral administration, a predictable effect, lack of frequent monitoring or re-dosing and few known drug interactions. To date, no Cochrane review has measured the effectiveness and safety of these drugs in the treatment of DVT. OBJECTIVES: To assess the effectiveness of oral DTIs and oral factor Xa inhibitors for the treatment of DVT. SEARCH METHODS: The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched January 2015) and the Cochrane Register of Studies (last searched January 2015). We searched clinical trials databases for details of ongoing or unpublished studies and the reference lists of relevant articles retrieved by electronic searches for additional citations. SELECTION CRITERIA: We included randomised controlled trials in which people with a DVT confirmed by standard imaging techniques, were allocated to receive an oral DTI or an oral factor Xa inhibitor for the treatment of DVT. DATA COLLECTION AND ANALYSIS: Two review authors (LR, JM) independently extracted the data and assessed the risk of bias in the trials. Any disagreements were resolved by discussion with the third review author (PK). We performed meta-analyses when we considered heterogeneity low. The two primary outcomes were recurrent VTE and PE. Other outcomes included all-cause mortality and major bleeding. We calculated all outcomes using an odds ratio (OR) with a 95% confidence interval (CI). MAIN RESULTS: We included 11 randomised controlled trials of 27,945 participants. Three studies tested oral DTIs (two dabigatran and one ximelagatran), while eight tested oral factor Xa inhibitors (four rivaroxaban, two apixaban and two edoxaban). We deemed all included studies to be of high methodological quality and low risk of bias. The quality of the evidence was graded as high as the outcomes were direct and effect estimates were consistent and precise, as reflected in the narrow CIs around the ORs. Meta-analysis of three studies (7596 participants) comparing oral DTIs with standard anticoagulation groups showed no difference in the rate of recurrent VTE (OR 1.09; 95% CI 0.80 to 1.49), recurrent DVT (OR 1.08; 95% CI 0.74 to 1.58), fatal PE (OR 1.00; 95% CI 0.27 to 3.70), non-fatal PE (OR 1.12; 95% CI 0.66 to 1.90) or all-cause mortality (OR 0.82; 95% CI 0.60 to 1.13). However, oral DTIs were associated with reduced bleeding (OR 0.68; 95% CI 0.47 to 0.98). Meta-analysis of eight studies (16,356 participants) comparing oral factor Xa inhibitors with standard anticoagulation demonstrated a similar rate of recurrent VTE between the two treatments (OR 0.89; 95% CI 0.73 to 1.07). Oral factor Xa inhibitors were associated with a lower rate of recurrent DVT (OR 0.75; 95% CI 0.57 to 0.98). However, this was a weak association, heavily dependent on one study. The rate of fatal (OR 1.20; 95% CI 0.71 to 2.03), non-fatal PE (OR 0.94; 95% CI 0.68 to 1.28) and all-cause mortality (OR 0.90; 95% CI 0.65 to 1.23) was similar between the two treatment groups. Oral factor Xa inhibitors were also associated with reduced bleeding (OR 0.57; 95% CI 0.43 to 0.76). None of the included studies measured post-thrombotic syndrome or health-related quality of life. AUTHORS' CONCLUSIONS: NOACs such as DTIs and factor Xa inhibitors may be an effective and safe alternative to conventional anticoagulation treatment for acute DVT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Schellong, S., Eriksson, H., Baanstra, D., Kvamme, A. M., Friedman, J., Mismetti, P., & Goldhaber, S. Z. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1113697 · Cited by 983
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
Boutitie, F., Pinede, L., Schulman, S., Agnelli, G., Raskob, G., Julian, J., Hirsh, J., & Kearon, C. (2011) · BMJ · doi:10.1136/bmj.d3036 · Cited by 371
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008) · Blood · doi:10.1182/blood-2008-05-160143 · Cited by 342
Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation · doi:10.1161/circulationaha.106.668020 · Cited by 337
Castellucci, L. A., Cameron, C., Le Gal, G., Rodger, M. A., Coyle, D., Wells, P. S., Clifford, T., Gandara, E., Wells, G., & Carrier, M. (2013) · BMJ · doi:10.1136/bmj.f5133 · Cited by 193
Research works printed but not linked: 78
- Agnelli, 2013, Apixaban was non-inferior to enoxaparin plus warfarin in patients with acute venous thromboembolism, Annals of Internal Medicine, 159, JC2, 10.7326/0003-4819-159-8-201310150-02002 · DOI
- Agnelli, 2013, Apixaban for the treatment of symptomatic deep-vein thrombosis and pulmonary embolism: a randomized, double-blind trial (AMPLIFY), Journal of Thrombosis and Haemostasis, 11, 18
- Barrett, 2011, Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis, Thrombosis and Haemostasis, 105, 181, 10.1160/TH10-06-0393 · DOI
- Buller HR A dose finding study of the oral direct factor Xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis - The Botticelli Investigators XXIst Congress of the International Society on Thrombosis and Haemostasis; 2007 Jul 6-12; Geneva 2007 · DOI · Paper page
- Buller, 2008, Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study, Journal of Thrombosis and Haemostasis, 6, 1313, 10.1111/j.1538-7836.2008.03054.x · DOI · Paper page
- Buller HR Agnelli G Once- or twice-daily rivaroxaban for the treatment of proximal deep vein thrombosis: similar efficacy and safety to standard therapy in dose-ranging studies Blood 2006 172 3 · DOI
- Bamber, 2013, Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis, Thrombosis and Haemostasis, 110, 732, 10.1160/TH13-03-0243 · DOI · Paper page
- Buller, 2010, Oral rivaroxaban for the acute and continued treatment of symptomatic venous thromboembolism. The Einstein-DVT and Einstein-Extension study, Blood (ASH Annual Meeting Abstracts), 116, 187
- Prins M Bamber L Cano S Wang M Lensing AWA Bauersachs R Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism Blood (ASH Annual Meeting Abstracts) 2012 1163 · DOI
- Prins, 2013, Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies, Thrombosis Journal, 11, 21, 10.1186/1477-9560-11-21 · DOI · Paper page
- Prins, 2013, Incidence of recurrent venous thromboembolism in patients following completion of the EINSTEIN DVT and EINSTEIN PE studies, Journal of Thrombosis and Haemostasis, 11, 257
- Bellen, 2014, Reduction in initial length of stay with rivaroxaban single-drug regimen versus LMWH-VKA standard of care: findings from the Einstein trial program, Current Medical Research and Opinion, 30, 829
- Wang, 2013, Rivaroxaban for the treatment of symptomatic deep vein thrombosis and/or pulmonary embolism in Chinese patients: a subgroup analysis of the EINSTEIN DVT and PE studies, Journal of Thrombosis and Haemostasis, 11, 694
- Prins, 2012, Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic pulmonary embolism, Blood (ASH Annual Meeting Abstracts), 120, 1163
- The Einstein-PE Investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, New England Journal of Medicine, 366, 1287, 10.1056/NEJMoa1113572 · DOI
- Raskob, 2013, Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study - methodological implications for clinical trials, Journal of Thrombosis and Haemostasis, 11, 1287, 10.1111/jth.12230 · DOI
- Piazza, 2014, A randomized, open-label, multicenter study of the efficacy and safety of edoxaban monotherapy versus low-molecular weight heparin/warfarin in patients with symptomatic deep vein thrombosis-edoxaban thrombus reduction imaging study (etris), Circulation, 130, A12074
- Schulman S Eriksson H Goldhaber S Kakkar AK Kearon C Kvamme AM Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism Journal of Thrombosis and Haemostasis 2011 22
- Schulman, 2013, Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II, Journal of Thrombosis and Haemostasis, 11, 225
- Schulman, 2009, Dabigatran versus warfarin in the treatment of acute venous thromboembolism, New England Journal of Medicine, 361, 2342, 10.1056/NEJMoa0906598 · DOI · Paper page
- Schulman, 2011, A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II), Blood, 118, 95, 10.1182/blood.V118.21.205.205 · DOI · Paper page
- Schulman, 2012, Benefit of extended maintenance therapy for venous thromboembolism with dabigatran etexilate is maintained over 1 year of post-treatment follow-up, Blood (ASH Annual Meeting Abstracts), 120, 21
- Schulman, 2013, Safety of dabigatran vs. warfarin for acute venous thromboembolism: pooled analyses of RE-COVER and RE-COVER II, Journal of Thrombosis and Haemostasis, 11, 225
- Schulman, 2013, Influence of age on the efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER and RE-COVER II, Blood (ASH Annual Meeting Abstracts), 122, 2375
- Schulman, 2014, Efficacy of dabigatran versus warfarin in patients with acute venous thromboembolism and thrombophilia: a pooled analysis of RE-COVER and RE-COVER II, Circulation, 130, A18594
- Eriksson, 2005, Prognostic factors for recurrence of venous thromboembolism (VTE) or bleeding during long-term secondary prevention of VTE with ximelagatran, Thrombosis and Haemostasis, 94, 522
- Eriksson, 2003, A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I, Journal of Thrombosis and Haemostasis, 1, 41, 10.1046/j.1538-7836.2003.00034.x · doi:10.1046/j.1538-7836.2003.00034.x
- Huisman MV The THRIVE Treatment Study Investigators Efficacy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis, with or without pulmonary embolism: a randomized, double-blind, multinational study Journal of Thrombosis and Haemostasis 2003 Abstract OC003
- Schulman, 2005, Ximelagatran for the secondary prevention of venous thromboembolism: a complementary follow-up analysis of the THRIVE III study 1828, Thrombosis and Haemostasis, 94, 820
- Wimperis, 2004, Ximelagatran, an oral direct thrombin inhibitor, compared with current standard therapy for acute, symptomatic deep vein thrombosis, with or without pulmonary embolism: the THRIVE Treatment Study, British Journal of Haematology, 125, 66
- Ageno, 2014, XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis, Thrombosis Journal, 12, 16, 10.1186/1477-9560-12-16 · DOI
- Agnelli, 2012, Two doses of apixaban for the extended treatment of venous thromboembolism, Blood (ASH Annual Meeting Abstracts), 120, LBA
- Liu X Thompson J Phatak H Mardekian J Porcari AR Johnson MR Apixaban reduces hospitalization in patients with venous thromboembolism: an analysis of the AMPLIFY-EXT trial Blood Conference: 55th Annual Meeting of the American Society of Hematology, ASH 2013 21 · doi:10.1182/blood.v122.21.3638.3638
- Schulman, 2013, Extended use of dabigatran, warfarin, or placebo in venous thromboembolism, New England Journal of Medicine, 368, 709, 10.1056/NEJMoa1113697 · DOI · Paper page
- Fiessinger, 2005, Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomised trial, JAMA, 293, 681, 10.1001/jama.293.6.681 · DOI · Paper page
- Schulman, 2003, Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran, New England Journal of Medicine, 349, 1713, 10.1056/NEJMoa030104 · DOI · Paper page
- Ageno, 2012, Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e44S, 10.1378/chest.11-2292 · DOI · Paper page
- Agnelli, 2007, Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study, Circulation, 116, 180, 10.1161/CIRCULATIONAHA.106.668020 · DOI · Paper page
- Agnelli, 2013, Oral apixaban for the treatment of acute venous thromboembolism, New England Journal of Medicine, 369, 799, 10.1056/NEJMoa1302507 · DOI · Paper page
- Antoniazzi S Berdai D Conti V Robinson P Radice S Clementi E Risk of major bleeding with dabigatran versus active controls: a systematic review and meta-analysis Congres de Physiologie de Pharmacolgoie et de Therapeutique
- Baetz, 2008, Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases, Pharmacotherapy, 28, 1354, 10.1592/phco.28.11.1354 · DOI
- Bates, 2012, Diagnosis of DVT: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, 141, e351S, 10.1378/chest.11-2299 · DOI · Paper page
- Buller, 2008, Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study, Journal of Thrombosis and Haemostasis, 6, 1313, 10.1111/j.1538-7836.2008.03054.x · DOI · Paper page
- Boudes, 2006, The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee, Contemporary Clinical Trials, 27, 432, 10.1016/j.cct.2006.04.005 · DOI
- Connolly, 2009, Dabigatran versus warfarin in patients with atrial fibrillation, New England Journal of Medicine, 361, 1139, 10.1056/NEJMoa0905561 · DOI · Paper page
- Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
- Eikelboom, 2010, Update on antithrombotic therapy: new anticoagulants, Circulation, 121, 1523, 10.1161/CIRCULATIONAHA.109.853119 · DOI · Paper page
- Bauersachs, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, New England Journal of Medicine, 363, 2499, 10.1056/NEJMoa1007903 · DOI · Paper page
- Eriksson, 2003, A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I, Journal of Thrombosis and Haemostasis, 1, 41, 10.1046/j.1538-7836.2003.00034.x · doi:10.1046/j.1538-7836.2003.00034.x
- Eriksson, 2007, Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial, Journal of Thrombosis and Haemostasis, 5, 2178, 10.1111/j.1538-7836.2007.02748.x · DOI · Paper page
- Eriksson, 2009, Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development, Clinical Pharmacokinetics, 48, 1, 10.2165/0003088-200948010-00001 · DOI · Paper page
- Fox, 2012, Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials, BMJ, 345, e7498, 10.1136/bmj.e7498 · DOI · Paper page
- Gomez-Outes, 2014, Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis, Thrombosis Research, 134, 774, 10.1016/j.thromres.2014.06.020 · DOI
- Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
- Hirschl, 2014, New oral anticoagulants in the treatment of acute venous thromboembolism - a systematic review with indirect comparisons, Vasa, 43, 353, 10.1024/0301-1526/a000373 · DOI
- Huerta, 2007, Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom, Archives of Internal Medicine, 167, 935, 10.1001/archinte.167.9.935 · DOI · Paper page
- Kahn, 2002, The post-thrombotic syndrome: current knowledge, controversies and directions for future research, Blood Reviews, 16, 155, 10.1016/S0268-960X(02)00008-5 · DOI · Paper page
- Kahn, 2014, Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial, The Lancet, 383, 880, 10.1016/S0140-6736(13)61902-9 · DOI · Paper page
- Kam, 2005, Direct thrombin inhibitors: pharmacology and clinical relevance, Anaesthesia, 60, 565, 10.1111/j.1365-2044.2005.04192.x · DOI
- Kang, 2014, Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism, Thrombosis Research, 133, 1145, 10.1016/j.thromres.2014.03.035 · DOI
- Koster, 2007, The direct thrombin inhibitor argatroban: a review of its use in patients with and without HIT, Biologics, 1, 105
- Lee, 2011, Direct thrombin inhibitors, British Journal of Clinical Pharmacology, 72, 581, 10.1111/j.1365-2125.2011.03916.x · DOI · Paper page
- Lewis, 2001, Clinical investigation and reports. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia, Circulation, 103, 1838, 10.1161/01.CIR.103.14.1838 · DOI · Paper page
- Oldgren, 2011, Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial, European Heart Journal, 32, 2781, 10.1093/eurheartj/ehr113 · DOI · Paper page
- Palladino, 2013, Evaluation of the oral direct factor Xa inhibitor - betrixaban, Expert Opinion on Investigational Drugs, 22, 1465, 10.1517/13543784.2013.825605 · DOI
- The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2012
- Robertson, 2014, Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010957 · DOI
- Sardar, 2013, Efficacy and safety or new oral anticoagulants for extended treatment of venous thromboembolism: systematic review and meta-analyses of randomised controlled trials, Drugs, 73, 1171, 10.1007/s40265-013-0082-7 · DOI
- Schulman, 2005, Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients, Journal of Thrombosis and Haemostasis, 3, 692, 10.1111/j.1538-7836.2005.01204.x · DOI · Paper page
- Schulman, 2011, A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RE-COVER II), Blood, 118, Abstract 205, 10.1182/blood.V118.21.205.205 · DOI · Paper page
- Spyropoulos, 2012, How I treat anticoagulated patients undergoing an elective procedure or surgery, Blood, 120, 2954, 10.1182/blood-2012-06-415943 · DOI · Paper page
- Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org
- Werf, 2012, A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN), American Heart Journal, 163, 931, 10.1016/j.ahj.2012.03.011 · DOI · Paper page
- Huille, 2014, Effectiveness and safety of novel anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis, Journal of Thrombosis and Haemostasis, 12, 320, 10.1111/jth.12485 · DOI · Paper page
- Warkentin, 1996, A 14-year study of heparin-induced thrombocytopenia, American Journal of Medicine, 101, 502, 10.1016/S0002-9343(96)00258-6 · DOI · Paper page
- Weitz, 2003, A novel approach to thrombin inhibition, Thrombosis Research, 109, S17, 10.1016/S0049-3848(03)00251-2 · doi:10.1016/s0049-3848(03)00251-2
- Wells, 2003, Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis, New England Journal of Medicine, 349, 1227, 10.1056/NEJMoa023153 · DOI · Paper page
- Robertson, 2014, Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD010956 · DOI
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
Antithrombotic Therapy for VTE Disease
Stevens, S. M., Woller, S. C., Kreuziger, L. B., Bounameaux, H., Doerschug, K., Geersing, G.-J., Huisman, M. V., Kearon, C., King, C. S., Knighton, A. J., et al. (2021) · Chest · doi:10.1016/j.chest.2021.07.055 · Cited by 1,043
Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis
Vedantham, S., Goldhaber, S. Z., Julian, J. A., Kahn, S. R., Jaff, M. R., Cohen, D. J., Magnuson, E., Razavi, M. K., Comerota, A. J., Gornik, H. L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615066 · Cited by 866
Villa, E., Bianchini, M., Blasi, A., Denys, A., Giannini, E. G., de Gottardi, A., Lisman, T., de Raucourt, E., Ripoll, C., & Rautou, P.-E. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.09.003 · Cited by 318
Metadata
- Authors
- Robertson, L., Kesteven, P., & McCaslin, J. E.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-06-30
- Issue
- 6
- Pages
- CD010956-CD010956
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1732278986
- Cited by
- 78
- References
- 12
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Update notices
- new_version (2023-04-14)
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.